Results 151 to 160 of about 22,236,668 (323)
Treatment-emergent adverse events.
Treatment-emergent adverse events affecting ≥15% of subjects treated with BG00010 (any dose) or ≥15% of subjects treated with placebo.i.v., intravenous; N/A, not applicable; s.c., subcutaneous.Treatment-emergent adverse events.
Jitesh Rana (737072) +6 more
core +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Background: Active tuberculosis drug-safety monitoring and management (aDSM) is recommended in the treatment of rifampicin-resistant tuberculosis. We established comprehensive aDSM and conducted a nationwide multicenter prospective study in Taiwan ...
Chou-Jui Lin +7 more
doaj +1 more source
Cutaneous Adverse Events Related To Treatment With Imatinib
Treatment with Imatinib is generally well-tolerated, and in the majority of patients side effects are only represented by mild to moderate haematological toxicity (Druker 2001).
SAVOIA, Paola, Fava Paolo
core
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng +4 more
wiley +1 more source
Background Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer.
Tadashi Nishimura +21 more
doaj +1 more source
Nazia Rashid,1 Han A Koh,2 Hilda C Baca,3 Kathy J Lin,1 Susan E Malecha,4 Anthony Masaquel5 1Drug Information Services, Kaiser Permanente, Downey, 2Southern California Permanente Medical Group, Kaiser Permanente, Bellflower, 3Pharmacy Analytical Services,
Koh HA +5 more
core
VL–visceral leishmaniasis*two of the renal impairments occurred in patients admitted for severe pneumonia who eventually died while on treatment. But as pentamidine is also known for its renal effect, they were considered as possibly pentamidine related ...
Fabiana Alves (217602) +15 more
core +1 more source
Treatment emergent adverse events (AEs).
Treatment emergent adverse events (AEs).
Andrea Kuemmerle (296573) +10 more
core +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source

